Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    



Fighting Breast Cancer with New Research, New Tools


 

Although many more will die from heart disease and lung cancer, breast cancer remains the most feared diagnosis for many women.

The bad news is it is the most common cancer among U.S. women with the exception of skin cancer. The good news is that death rates have dropped over the years and new treatment options continue to come online.

The American Cancer Society estimates about 252,710 new cases of invasive breast cancer and 63,410 new cases of carcinoma in situ cases will be diagnosed in 2017. Additionally, the ACS estimates 40,610 women will die from breast cancer this year.

The second leading cause of cancer death in women, the death rate declined by 38 percent from a peak high in 1989 until 2014 (the last year for which figures are currently available). The ACS "Cancer Facts & Figures 2017" attributes the drop, which cumulatively translates to almost 300,000 fewer deaths from breast cancer, to improvements in early detection and treatment.

Localized cancer, which makes up more than 60 percent of newly diagnosed cases, has a five-year relative survival rate of 99 percent. Invasive breast cancer has a 90 percent five-year survival. Today, there are more than 3.1 million breast cancer survivors in the United States.


Primary Prevention: Diet Matters


Karin Michels, ScD, PhD,

A study released earlier this year in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research, found poor diet in adolescence and early adulthood is linked to an increased risk of premenopausal breast cancer. Specifically, the study pointed to a diet associated with chronic inflammation that was low in vegetables and high in carbohydrates, refined sugar, and processed meats as being a culprit for significantly increased risk, according to Karin Michels, ScD, PhD, lead author and professor and chair of the Department of Epidemiology at the UCLA Fielding School of Public Health.

"Because breast cancer takes many years to arise, we were curious whether such a diet during the early phases of a woman's life is a risk factor for breast cancer," she said.

The research team used data from 45,204 women in the Nurses' Health Study II who had previously completed food frequency questionnaires about diet during high school and later questionnaires about eating habits at various stages of adulthood. Michels and colleagues then assigned an inflammatory score based on the women's adolescent diet and created five groupings.

During 22 years of follow-up, 870 women were diagnosed with premenopausal breast cancer. Those who were in the top inflammatory score group from adolescence had a 35 percent higher risk for premenopausal breast cancer than those in the lowest score group. The researchers then used the same method to score early adulthood diet based on the later questionnaires. When the analysis was run using that data, women in the highest inflammatory score group had a 41 percent higher risk for premenopausal breast cancer relative to those in the lowest score group.

"Our results suggest that a habitual diet that promotes chronic inflammation when consumed during adolescence or early adulthood may indeed increase the risk of breast cancer in younger women before menopause," said Michels.

Recognizing each woman's breast cancer risk is different based on a host of factors from demographics to genetic predisposition to lifestyle choices, Michels said this study points to poor diet as yet another potential factor to consider. While not definitive -Michels noted the study had several limitations including the fact that adolescent diet was recalled at a later date by participants and that researchers did not have access to adolescent and early adulthood measurements of blood markers of inflammation - she noted consuming a healthier diet when young appeared to afford some protection.

Michels concluded, "During adolescence and early adulthood, when the mammary gland is rapidly developing and is therefore particularly susceptible to lifestyle factors, it is important to consume a diet rich in vegetables, fruit, whole grains, nuts, seeds, and legumes and to avoid soda consumption and a high intake of sugar, refined carbohydrates, and red and processed meats."


HER2 Treatment Targets

Moffitt Cancer Center researchers in Tampa, Fla., have reported promising clinical activity with a HER2-targeted dendritic cell vaccine. Since deregulation and inhibition of the immune system help cancer develop and proliferate, researchers worldwide have focused energies on therapeutic strategies to re-stimulate the immune system and get it to recognize and destroy cancer cells.

Previous research has shown immune cells are less likely to recognize and target cancer cells that express HER2 as the breast cancer progresses to a more advanced stage. The vaccine being studied targets the HER2 protein on breast cancer cells using dendritic cells harvested from each patient for a personalized vaccine and led to regression of early-stage breast cancer with minimal toxicities.

Moffitt researchers performed the clinical trial in 54 women who had HER2-expressing, early-stage breast cancer. After isolating each woman's dendritic cells and exposing them to fragments of HER2 protein, the women received an injection of their personalized vaccine weekly for six weeks into a lymph node, the breast tumor, or both.

Assessing the vaccine's effectiveness by seeing how many of the women had detectable disease in surgical specimens after resection, researchers found 13 patients achieved a pathological complete response (pCR). Of that group, patients with ductal carcinoma in situ (DCIS) achieved a higher rate of pCR than those with early-stage invasive disease, and those who achieved a pCR had a higher immune response within their local sentinel lymph nodes.

Brian J. Czerniecki, MD, PhD, chair of the Department of Breast Oncology at Moffitt, said, "These results suggest that vaccines are more effective in DCIS, thereby warranting further evaluation in DCIS or other minimal disease settings, and the local regional sentinel lymph node may serve as a more meaningful immunologic endpoint."

In other news, the U.S. Food and Drug Administration approved a new drug in March from Novartis Pharmaceuticals for the treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer.

Ribociclib (Kisqali), a cyclin-dependent kinase 4/6 inhibitor, was approved in combination with an aromatese inhibitor as initial endocrine-based therapy based on interim results from the international MONALEESA-2 trial. In the randomized trial, those receiving ribociclib plus letrozole (the aromatese inhibitor) reduced the risk of progression or death by 44 percent compared to those receiving letrozole alone and demonstrated tumor burden reduction with an overall 53 percent response rate.

Novartis has since reported information from a subsequent analysis with additional follow-up and progression events that showed a median progression-free survival of 25.3 months for ribociclib with letrozole compared to 16 months for letrozole alone.

RELATED LINKS:
American Association for Cancer Research
Moffitt Cancer Center
Novartis Release on Ribociclib

 
Share:

Related Articles:


Recent Articles

Increasing Number Of Tennesseans Dying From Drug Overdoses

Tennessee Department of Health data show 1,631 Tennesseans died from drug overdoses in 2016, the highest annual number of such deaths recorded in state history. This is an increase from the 1,451 overdose deaths recorded among Tennessee residents in 2015.

Read More

AMA Urges Congress to Take Swift Action to Retain DACA Program Protections

The American Medical Association sent a letter to Congress on Sept. 5 outlining why DACA is an American healthcare issue and urging legislators to take prompt action to ensure individuals with Deferred Action for Childhood Arrivals status are able to remain in the United States.

Read More

New Antiviral Drug Inhibits Epidemic SARS, MERS & More

A multi-institutional team of researchers has found a new antiviral drug candidate that could treat or prevent a number of potential pandemic outbreaks.

Read More

Disaster Preparedness: Are We Ready?

In a world of ever-evolving threats, the officials responsible for a community's health and safety must constantly update, evaluate, prepare and communicate their preparedness plan.

Read More

Addressing Opioid Addiction in America

Even as the AMA works with physicians and other providers to address opioid addiction, the national epidemic continues to evolve.

Read More

Moving Forward on Health Reform

THA's Craig Becker shares the hospital perspective on healthcare reform and what's needed to maintain access to care across Tennessee.

Read More

MGMA Releases 2017 Regulatory Burden Survey: MIPS Tops the List

The results of the Medical Group Management Association (MGMA) 2017 Regulatory Burden Survey reveal there is no shortage of opportunity to reduce regulatory burdens on physician practices.

Read More

In Case of Emergency

On Sept. 8, 2016 the final rule Emergency Preparedness Requirements for Medicare and Medicaid Participating Providers and Suppliers was published in the Federal Register. By Nov. 16, 2017, providers and suppliers must be in compliance.

Read More

Innovative Meharry Program Helps Mothers with Opioid Addiction

The Rainbow Program at Meharry offers pregnant and postpartum women with substance abuse disorders new hope.

Read More

The Osher Center: Healing Mind, Body & Spirit

Multi-faceted approach to pain management blends old and new therapies at The Osher Center for Integrative Medicine at Vanderbilt

Read More

Email Print
 
 

 

 


Tags:
ACS, American Association for Cancer Research, American Cancer Society, Breast Cancer, HER2 Breast Cancer, HER2-Targeted Dendritic Cell Vaccine, Karin Michels, Kisqali, Letrozole, Moffitt Cancer Center, MONALEESA-2, Novartis, Premenopausal Breast Cancer, Ribociclib, UCLA Fielding School of Public Health
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: